Phase 1b/2a of CNP-201 in Subjects With Peanut Allergy
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 1b/2a randomized, double-blind, placebo-controlled clinical trial to
assess the safety, tolerability, and pharmacodynamics of multiple ascending doses of CNP-201
with the goal of identifying a safe and tolerable dose level.